Patents Assigned to Natreon, Inc.
-
Publication number: 20160213644Abstract: A method of using dibenzo-alpha-pyrones (DBPs) is provided wherein a subject is administered one or more of the aforementioned resulting in decreased body weight gain. In an embodiment, a 3-OH-DBP, 3,8-(OH)2-DBP, or a combination thereof is administered to an individual to control body weight gain.Type: ApplicationFiled: September 9, 2014Publication date: July 28, 2016Applicant: Natreon, Inc.Inventor: Chandan K. Sen
-
Patent number: 9393281Abstract: Compositions including combinations of ?-glucan and Withania somnifera for increasing the immune activity of certain target cytokines and phagocytosis, and reducing cortisol or corticosterone. Methods of improving immunity activity under periods of stress including chronic stress with a combination of ?-glucan and Withania somnifera are also described. Particular combinations of ?-glucan and Withania somnifera synergistically increases the immune activity of the cytokines IL-12 and IL-6 over expected values.Type: GrantFiled: December 2, 2013Date of Patent: July 19, 2016Assignees: Nutragenesis, LLC, Natreon, Inc.Inventor: Peter S. McNeary
-
Publication number: 20160074452Abstract: Chromium-three cation containing compositions in synergistic combination with Phyllanthus emblica extract and Shilajit are useful for improvement of endothelial function and cardiovascular health, including treatment of type 2 diabetes and metabolic syndrome.Type: ApplicationFiled: November 20, 2015Publication date: March 17, 2016Applicant: NATREON, INC.Inventor: Sanyasi R. Kalidindi
-
Publication number: 20160015740Abstract: Chromium-three cation containing compositions in combination with Phyllanthus emblica extract and Shilajit are useful for improvement of endothelial function and cardiovascular health, including treatment of type 2 diabetes and metabolic syndrome.Type: ApplicationFiled: May 21, 2015Publication date: January 21, 2016Applicant: Natreon, Inc.Inventor: Sanyasi R. Kalidindi
-
Publication number: 20150320771Abstract: A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.Type: ApplicationFiled: July 21, 2015Publication date: November 12, 2015Applicant: NATREON, INC.Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
-
Patent number: 9084800Abstract: A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.Type: GrantFiled: November 5, 2012Date of Patent: July 21, 2015Assignee: Natreon, Inc.Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
-
Publication number: 20150174184Abstract: The present invention provides an optimized and/or enriched hydrolyzable tannoid blend derived from Terminalia chebula. In an embodiment the present invention further relates to the use of an extract of Terminalia chebula for treatment of osteoarthritis. In another embodiment, a T. chebula extract composition contains about 8-25% by weight chebulagic acid, about 15-30% by weight chebulinic acid and about 10-40% by weight other low molecular weight hydrolyzable tannoids. This embodiment provides a T. chebula enriched tannoid blend composition (TC/enriched tannoid blend). In another embodiment, a method of treating osteoarthritis in an individual is provided, comprising administering to the individual in need thereof a therapeutically effective amount of the T. chebula extract composition.Type: ApplicationFiled: December 22, 2014Publication date: June 25, 2015Applicant: NATREON, INC.Inventor: Sanyasi R. Kalidindi
-
Patent number: 8962576Abstract: Compositions of natural antioxidants, especially those derived from Phyllanthus emblica and Withania somnifera, and combinations thereof, are provided. The compositions may be used for improvement of endothelial function and cardiovascular health, including treatment of diabetes.Type: GrantFiled: March 26, 2013Date of Patent: February 24, 2015Assignee: Natreon, Inc.Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
-
Publication number: 20150050369Abstract: Compositions containing extracts of Terminalia chebula and Terminalia bellerica, or combinations thereof and methods for treatment of uricemia, hyperuricemia, and gout in a human subject are provided.Type: ApplicationFiled: August 13, 2014Publication date: February 19, 2015Applicant: NATREON, INC.Inventor: Sanyasi R. Kalidindi
-
Publication number: 20140356466Abstract: Chromium-three cation in combination with Phyllanthus emblica extract and Shilajit is useful in treating symptoms associated with osteoarthritis including reduction of inflammation and pain in a mammal, particularly a human or an animal. The combination shows significant reduction in overall pain levels and other pain measures in a canine model, and in human studies. Thus the composition is an anti-arthritic formulation that decreases pain and inflammation.Type: ApplicationFiled: June 2, 2014Publication date: December 4, 2014Applicant: Natreon, Inc.Inventors: Ramesh C. Gupta, Aundrea Fleck, Sanyasi R. Kalidindi
-
Patent number: 8894993Abstract: The present invention relates to a pharmaceutical or veterinary or nutritional or personal care composition comprising coenzyme Q10 (CoQ10), reduced CoQ10, or mixtures thereof and oxygenated dibenzo-?-pyrone or an amino acyl ester thereof. The composition of the present invention is able to support and/or provide therapy to individuals at risk and/or under treatment for dysfunctions of energy metabolism, and specifically, for mitochondrial diseases.Type: GrantFiled: July 27, 2007Date of Patent: November 25, 2014Assignees: Natreon Inc., Indian Herbs Research & Supply Company, Ltd.Inventor: Shibnath Ghosal
-
Publication number: 20140079729Abstract: Shilajit in a standardized composition produces a significant improvement in several cardiovascular parameters including RI, AIx and SEVR. Further, significant reductions in malondialdehyde and increases in nitric oxide levels are provided suggesting improvement in endothelial function. Shilajit may be used to reduce inflammatory biomarker HsCRP levels significantly compared to baseline and placebo. Additionally, Shilajit can provide significant improvement in lipid parameters including total cholesterol, LDL-C, and HbA1c (%) Inhibition of platelet aggregation using Shilajit performed using ADP as aggregant also provides highly significant inhibition of platelet aggregation compared to baseline and with placebo. Thus, Shilajit may be used for improvement of endothelial function and to help reduce cardiovascular morbidity, particularly for the diabetic individual.Type: ApplicationFiled: September 13, 2013Publication date: March 20, 2014Applicant: Natreon, Inc.Inventor: Sanyasi R. Kalidindi
-
Publication number: 20130266676Abstract: An enriched hydrolyzable tannoid blend derived from Terminalia chebula is provided. An optimized aqueous extraction method for Terminalia chebula is provided to maximize the levels of bioactive hydrolyzable tannoids including chebulagic acid, chebulinic acid and other low molecular weight hydrolyzable tannoids. The method produces a Terminalia chebula extract containing a hydrolyzable tannoid blend as an amorphous dry powder. In an embodiment, the Terminalia chebula extract contains 8-25% by weight chebulagic acid, 15-30% chebulinic acid, and 5-45% low molecular weight hydrolyzable tannoids. Potential uses of said enriched hydrolyzable tannoid compositions for antioxidant activity in a human subject are described herein.Type: ApplicationFiled: April 9, 2013Publication date: October 10, 2013Applicant: Natreon, Inc.Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
-
Publication number: 20130261068Abstract: Compositions of natural antioxidants, especially those derived from Phyllanthus emblica and Withania somnifera, and combinations thereof, are provided. The compositions may be used for improvement of endothelial function and cardiovascular health, including treatment of diabetes.Type: ApplicationFiled: March 26, 2013Publication date: October 3, 2013Applicant: Natreon, Inc.Inventors: Shibnath Ghosal, Muruganandam Veeraragavan, Sanyasi R. Kalidindi
-
Publication number: 20130122119Abstract: An enriched hydrolyzable tannin blend derived from Phyllanthus amarus is provided. An optimized aqueous extraction method for Phyllanthus amarus is provided to maximize the levels of bioactive hydrolyzable tannins including corilagin, geraniin, nirurin and other low molecular weight hydrolyzable tannoids. The method produces a Phyllanthus amarus extract containing a hydrolyzable tannin blend as an amorphous dry powder. In an embodiment, the Phyllanthus amarus extract contains 7-13% by weight corilagin, 3.5-10% nirurin, 1-2% geraniin, and 9-20% low molecular weight hydrolyzable tannoids. In another embodiment, the Phyllanthus amarus extract contains 12-20% geraniin and 12-20% low molecular weight hydrolyzable tannoids. Potential uses of said enriched hydrolyzable tannin compositions for hepatoprotection in a human subject are described herein.Type: ApplicationFiled: November 1, 2012Publication date: May 16, 2013Applicant: NATREON, INC.Inventor: Natreon, Inc.
-
Publication number: 20130115316Abstract: A group of indolealkylamino-withasteroid conjugates, isolated and purified from Withania somnifera, are described. A synthetic method of making an indolealkylamino-withasteroid compound is provided. In vitro acetyl cholinesterase inhibitory activity and methods for treatment of dementia and dementia-related disorders, such as Alzheimer's disease, and anxiety and depressive disorders in mammals are demonstrated with these novel compositions.Type: ApplicationFiled: November 5, 2012Publication date: May 9, 2013Applicant: NATREON, INC.Inventor: Natreon, Inc.
-
Patent number: 8206757Abstract: A therapeutic composition comprising extracts of the plant species ashwagandha (Withania somnifera) and Indian gooseberry (Phyllanthus emblica). A composition of ashwagandha and Indian gooseberry may: (1) lower cortisol and increase DHEA, (2) prevents free radical-induced photoaging, (3) inhibit collagenase activity in vitro, (4) inhibit hyaluronidase activity in vitro, (5) display superior cascading antioxidant activity, (6) reduce C-reactive protein, (7) enhance mood.Type: GrantFiled: October 22, 2009Date of Patent: June 26, 2012Assignees: Nutragenesis, LLC, Natreon, Inc.Inventor: Peter McNeary
-
Patent number: 7318938Abstract: This invention relates to a composition of the plant Withania Somnifera, and, more particularly to a high purity extract composition with advantageous levels of withanolide glycosides and oligosaccharides, a minimum of polysaccharides, and substantially low levels of free withaferin A and equivalents (withanolide aglycones), which composition provides enhanced cognition-enhancing effects for the user, and an extraction process for obtaining such composition, as well as pharmaceutical, nutritional and personal care use products thereof.Type: GrantFiled: February 26, 2004Date of Patent: January 15, 2008Assignees: Natreon, Inc., Indian Herbs Research & Supply Co., Ltd.Inventor: Shibnath Ghosal
-
Patent number: 7250181Abstract: The present invention relates to pharmaceutical or veterinary or nutritional compositions of polyherbal extracts useful as anti-viral or immune-supporting agents. Particularly, the present invention of polyherbal composition comprises of extracts of Withania somnifera, Mangifera indica and purified Shilajit. This cost effective immune-supporting agent is ideal for use during the maintenance phase of the treatment, following an initial viral load reduction phase in which it is used as an adjuvant to conventional anti-viral drug therapy. The anti-viral and immune-supporting composition of this invention can perhaps be the sole basis of treatment where affordability is an issue. Additionally, this composition is used for the treatment, prevention or management of immune-supporting system in primates in need, especially humans.Type: GrantFiled: January 19, 2005Date of Patent: July 31, 2007Assignee: Natreon, Inc.Inventor: Shibnath Ghosal
-
Patent number: 6869612Abstract: A purified shilajit composition is provided herein from native shilajit. The composition has an abundance of bioactive components, particularly, at least 0.3%, preferably 0.4-1%, by weight, oxygenated dibenzo-?-pyrones and at least 60%, preferably 65-70%, by weight of fulvic acids of low-to-medium molecular weight ({overscore (M)}n of 700-2000) with an E4/E6 ratio of 8-10 at ?465-665 nm, and whose 2% aqueous solution has a pH of ?7. Personal care, pharmaceutical and nutritional use formulations of the purified shilajit composition also are described.Type: GrantFiled: August 1, 2002Date of Patent: March 22, 2005Assignees: Natreon, Inc., Indian Herbs Research & Supply Company Ltd.Inventor: Shibnath Ghosal